{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T15:11:00Z","timestamp":1772464260802,"version":"3.50.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>This study aimed to evaluate the utility of a commercial kit used to measure serum vancomycin concentrations to determine vancomycin concentrations in cerebrospinal fluid (CSF) samples and evaluate CSF penetration when administered as a continuous high-dose infusion in patients with nosocomial ventriculitis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This study included patients with external ventricular drain infection who were admitted to the intensive care unit between January 2018 and September 2020. After validation, CSF samples from 33 patients were collected. All patients received 30 mg\/kg of vancomycin as a loading dose followed by 60 mg\/kg as a maintenance dose in continuous infusion; all CSF samples were collected at least 48 hours after the first dose.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Thirty-three patients were enrolled in this study. The median serum creatinine level was 0.66 mg\/dL (0.5\u20130.92; n = 30), and median creatinine clearance was 119.2 mL\/min (64.6\u2013138.4; n = 13). The median serum vancomycin 24-hour area under the curve (AUC<jats:sub>24h<\/jats:sub>) was 838 mg*h\/L (515\u20131010). The median CSF vancomycin concentration was 5.20 mg\/L (1.95\u201312.4). Median serum vancomycin concentration was 34.9 mg\/L (21.47\u201342.1), and median CSF\/serum ratio was 18.6% (8.4\u201341.5). Acute renal injury occurred in 21% (n = 7) of the patients by the end of the therapy. In addition, the vancomycin CSF\/serum ratio was positively correlated with the median serum creatinine level (r = 0.670; <jats:italic toggle=\"yes\">P =<\/jats:italic> 0.004).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Commercial vancomycin kits used to measure serum samples may be used to evaluate vancomycin concentrations in the CSF. Vancomycin penetration into CSF was 18.6%.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000907","type":"journal-article","created":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T00:00:19Z","timestamp":1623715219000},"page":"807-811","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Cerebrospinal Fluid Penetration of Vancomycin During Continuous Infusion Therapy in Patients With Nosocomial Ventriculitis"],"prefix":"10.1097","volume":"43","author":[{"given":"Felipe Francisco","family":"Tuon","sequence":"first","affiliation":[{"name":"School of Medicine, Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1, Curitiba, PR, Brazil;"},{"name":"Laboratory of Emerging Infectious Diseases (LEID), School of Medicine, Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1, Curitiba, PR, Brazil;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina Hikari","family":"Yamada","sequence":"additional","affiliation":[{"name":"School of Medicine, Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1, Curitiba, PR, Brazil;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliette","family":"Cieslinski","sequence":"additional","affiliation":[{"name":"School of Medicine, Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1, Curitiba, PR, Brazil;"},{"name":"Laboratory of Emerging Infectious Diseases (LEID), School of Medicine, Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1, Curitiba, PR, Brazil;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dayana","family":"dos Santos Oliveira","sequence":"additional","affiliation":[{"name":"Hospital Universit\u00e1rio Cajuru, Curitiba, PR, Brazil; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria Stadler Tasca","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"School of Medicine, Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1, Curitiba, PR, Brazil;"},{"name":"Laboratory of Emerging Infectious Diseases (LEID), School of Medicine, Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1, Curitiba, PR, Brazil;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliano","family":"Gasparetto","sequence":"additional","affiliation":[{"name":"School of Medicine, Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1, Curitiba, PR, Brazil;"},{"name":"Hospital Universit\u00e1rio Cajuru, Curitiba, PR, Brazil; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joao Paulo","family":"Telles","sequence":"additional","affiliation":[{"name":"School of Medicine, Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1, Curitiba, PR, Brazil;"},{"name":"Laboratory of Emerging Infectious Diseases (LEID), School of Medicine, Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1, Curitiba, PR, Brazil;"},{"name":"Department of Infectious Diseases, AC Camargo Cancer Center, SP, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3171\/JNS\/2008\/109\/10\/0765","article-title":"The legendary contributions of Thomas Willis (1621-1675): the arterial circle and beyond","volume":"109","author":"Rengachary","year":"2008","journal-title":"J Neurosurg."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1001\/jama.2018.2089","article-title":"Trends and patterns of differences in infectious disease mortality among US counties, 1980\u20132014","volume":"319","author":"El Bcheraoui","year":"2018","journal-title":"JAMA."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ncl.2008.03.013","article-title":"Update in the diagnosis and management of central nervous system infections","volume":"26","author":"Ziai","year":"2008","journal-title":"Neurol Clin."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cmi.2017.05.013","article-title":"Management of post-neurosurgical meningitis: Narrative review","volume":"23","author":"Hussein","year":"2017","journal-title":"Clin Microbiol Infect."},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/MD.0b013e318243442b","article-title":"Methicillin-resistant Staphylococcus aureus meningitis in adults: a multicenter study of 86 cases","volume":"91","author":"Pintado","year":"2012","journal-title":"Medicine."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.bjid.2020.07.001","article-title":"Comparison of intermittent versus continuous-infusion vancomycin for treating severe patients in intensive care units","volume":"24","author":"Yamada","year":"2020","journal-title":"Braz J Infect Dis."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijantimicag.2015.10.019","article-title":"Continuous versus intermittent infusion of vancomycin in adult patients: a systematic review and meta-analysis","volume":"47","author":"Hao","year":"2016","journal-title":"Int J Antimicrob Agents."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s40262-017-0548-y","article-title":"Penetration of vancomycin into the cerebrospinal fluid: a systematic review","volume":"56","author":"Beach","year":"2017","journal-title":"Clin Pharmacokinet."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1128\/AAC.43.4.876","article-title":"Pharmacodynamics of vancomycin for the treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis","volume":"43","author":"Ahmed","year":"1999","journal-title":"Antimicrob Agents Chemother."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1093\/cid\/ciw861","article-title":"Infectious diseases society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis","volume":"64","author":"Tunkel","year":"2017","journal-title":"Clin Infect Dis."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/515003","article-title":"Antibiotic pharmacodynamics in cerebrospinal fluid","volume":"27","author":"Lutsar","year":"1998","journal-title":"Clin Infect Dis."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/jcpt.12770","article-title":"Comparation of vancomycin penetration into cerebrospinal fluid in postoperative intracranial infection and community-acquired meningitis patients","volume":"44","author":"Cai","year":"2019","journal-title":"J Clin Pharm Ther."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s12975-011-0125-x","article-title":"Blood-brain barrier pathophysiology in traumatic brain injury","volume":"2","author":"Chodobski","year":"2011","journal-title":"Transl Stroke Res."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/jac\/dky543","article-title":"CSF penetration of vancomycin in critical care patients with proven or suspected ventriculitis: a prospective observational study","volume":"74","author":"Blassmann","year":"2019","journal-title":"J Antimicrob Chemother."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF00165710","article-title":"Pharmacokinetics of intraventricular administration","volume":"1","author":"Collins","year":"1983","journal-title":"J Neurooncol."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ijantimicag.2019.08.002","article-title":"Intrathecal or intraventricular antimicrobial therapy for post-neurosurgical intracranial infection due to multidrug-resistant and extensively drug-resistant gram-negative bacteria: a systematic review and meta-analysis","volume":"54","author":"Hu","year":"2019","journal-title":"Int J Antimicrob Agents."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"e01684","DOI":"10.1128\/AAC.01684-17","article-title":"Identification of vancomycin exposure-toxicity thresholds in hospitalized patients receiving intravenous vancomycin","volume":"62","author":"Zasowski","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.2147\/IDR.S184897","article-title":"Vancomycin trough level and loading dose","volume":"11","author":"Tuon","year":"2018","journal-title":"Infect Drug Resist."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ijantimicag.2009.07.011","article-title":"Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy","volume":"34","author":"Ingram","year":"2009","journal-title":"Int J Antimicrob Agents."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jac\/dkr442","article-title":"Continuous versus intermittent infusion of vancomycin for the treatment of gram-positive infections: systematic review and meta-analysis","volume":"67","author":"Cataldo","year":"2012","journal-title":"J Antimicrob Chemother."},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jinf.2014.06.010","article-title":"Determination of vancomycin trough level in serum and cerebrospinal fluid of patients with acute community-acquired meningitis: a prospective study","volume":"69","author":"Shokouhi","year":"2014","journal-title":"J Infect."},{"key":"R22-20250603","first-page":"1","article-title":"Population pharmacokinetics of vancomycin in patients with external ventricular drain-associated ventriculitis","author":"Jalusic","year":"2020","journal-title":"Br J Clin Pharmacol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000907","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:09:14Z","timestamp":1748970554000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000907","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"2021-03-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}